Dr. Anas Younes received his medical degree from the University of Damascus School of Medicine in Syria. He completed residencies in pathology at the Medical College of Ohio and in internal medicine at SUNY Downstate Medical Center, as well as a fellowship in hematology/oncology at Memorial Sloan Kettering Cancer Center (MSKCC). Dr. Younes is Chief of Memorial Sloan Kettering's Lymphoma Service, Division of Hematologic Oncology, where he is responsible for continuing to accelerate the translation of scientific discoveries into novel treatment strategies to improve the cure rate and survival of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

Dr. Younes serves on the Scientific Advisory Board of the Lymphoma Research Foundation. He is a past member of the National Cancer Institute Lymphoma Steering Committee. He has served as the principal investigator of more than 60 clinical trials and has led the National Cancer Institute-funded SPORE (Specialized Programs of Research Excellence) in lymphoma both at MD Anderson Cancer Center and, most recently, at MSKCC. He is also the principal investigator of a SCOR grant supported by the Leukemia & Lymphoma Society. Dr. Younes has published more than 250 papers. His interests include HL, NHL, developing novel targeted therapies for lymphoma, identification of biomarkers for treatment, and participation in clinical trials. Dr. Younes led the trials that resulted in the FDA approval of brentuximab vedotin and nivolumab for the treatment of patients with relapsed Hodgkin lymphoma.